Latest Merger & Acquisition Healthcare News

Viemed Healthcare Announces Successful Completion of HMP Acquisition

June 1
Last Trade: 9.80 -0.06 -0.61

LAFAYETTE, La., June 01, 2023 (GLOBE NEWSWIRE) -- Viemed Healthcare, Inc. (the “Company” or “Viemed”) (NASDAQ:VMD and TSX:VMD.TO), a national leader in respiratory care and technology-enabled home medical equipment services, announced that it has successfully completed its previously announced acquisition of Tennessee based Home Medical Products, Inc. (“HMP”), a large regional provider of respiratory focused home medical solutions. “I’m...Read more

Adaptimmune Therapeutics Announces Completion of Strategic Combination with TCR2 Therapeutics Creating a Preeminent Solid Tumor Cell Therapy Company

June 1
Last Trade: 1.08 -0.01 -0.92

First marketed engineered T-cell therapy for a solid tumor; BLA for afami-cel on track to complete submission in mid-2023 Compelling clinical data with late-stage programs targeting MAGE-A4 and mesothelin Preclinical programs targeting PRAME and CD70 in IND-enabling studies Adaptimmune funded into early 2026 with multiple value creating catalysts Webcast to be held tomorrow, June 2nd at 8 a.m. EDT:...Read more

Elicio Therapeutics Announces Completion of Merger with Angion Biomedica

June 1
Last Trade: 18.15 0.00 0.00

Shares of Elicio to commence trading on Nasdaq under the ticker symbol “ELTX” on June 2, 2023 First in human Phase 1 data on lead candidate ELI-002 to be presented at 2023 American Society of Clinical Oncology (ASCO) BOSTON, June 01, 2023 (GLOBE NEWSWIRE) -- Elicio Therapeutics (Nasdaq: ELTX), a clinical-stage biotechnology company developing a pipeline of novel immunotherapies for the treatment of cancer, today announced the...Read more

Reunion Neuroscience Announces US$13.1 Million Take-Private Transaction with MPM BioImpact

June 1
Last Trade: 1.10 0.01 0.92

Reunion Common Shareholders to Receive Consideration of US$1.12 Per Share in Cash Represents a 43.1% Premium to the 30-Day Volume Weighted Average Price Reunion Presents Encouraging Phase 1 Final Analysis at American Society of Clinical Psychopharmacology Annual Meeting, Enabling Advancement into Phase 2 in 2H 2023 TORONTO, June 01, 2023 (GLOBE NEWSWIRE) -- Reunion Neuroscience Inc. (NASDAQ: REUN, TSX: REUN) (“Reunion” or the...Read more

U.S. Physical Therapy Announces Acquisition of a Four-Clinic Physical Therapy Practice

May 31
Last Trade: 106.00 3.02 2.93

HOUSTON / May 31, 2023 / Business Wire / U.S. Physical Therapy, Inc. ("USPH" or the “Company”) (NYSE: USPH), a national operator of outpatient physical therapy clinics and provider of industrial injury prevention services, today announced an acquisition of a physical therapy practice with four clinics. USPH and its local partners together acquired a 75% equity interest in the practice for a purchase price of $3.1 million, with the current...Read more

Seagen Stockholders Approve Acquisition by Pfizer

May 30
Last Trade: 195.38 0.71 0.36

BOTHELL, Wash. / May 30, 2023 / Business Wire / Following a special meeting of its stockholders, Seagen Inc. (Nasdaq: SGEN) today announced that its stockholders voted to approve a proposal to adopt the previously announced merger agreement under which Pfizer will acquire Seagen for $229 per share in cash. More than 99% of the shares voted at the meeting, representing approximately 88% of the shares of Seagen common stock issued and...Read more

MEI Pharma Confirms Receipt of Unsolicited Acquisition Proposal

May 30
Last Trade: 7.50 -0.05 -0.66

SAN DIEGO / May 30, 2023 / Business Wire / MEI Pharma, Inc. (NASDAQ: MEIP) (the “Company”) today confirmed receipt of an unsolicited and non-binding proposal on May 23, 2023 from a group represented by Anson Advisors Inc. and Cable Car Capital LLC, as referenced in their 13-D filing of earlier today, to acquire all outstanding shares of MEI for not less than $8.00 in cash per share, plus a contingent value right representing the right to...Read more

SeqLL Enters into a Definitive Merger Agreement with Lyneer Staffing Solutions and Atlantic Acquisition

BILLERICA, Mass., May 30, 2023 (GLOBE NEWSWIRE) -- SeqLL Inc. (“SeqLL” or the “Company”) (Nasdaq: SQL, SQLLW), a technology company providing life sciences instrumentation and research services, today announced that it has entered into a definitive merger agreement (the “Merger Agreement”) with Lyneer Investments, LLC (“Lyneer”), the indirect parent company of Lyneer Staffing Solutions, LLC and Atlantic Acquisition Corp. (“Atlantic”), and...Read more

Medtronic to acquire wearable insulin patch maker EOFlow

May 25
Last Trade: 83.76 1.01 1.22

Acquisition will expand company's ability to serve more people living with diabetes around the world within one seamless Medtronic ecosystem of support DUBLIN and SEONGNAM, South Korea, May 25, 2023 /CNW/ -- Medtronic plc (NYSE:MDT), a global leader in healthcare technology, today announced it has entered into a set of definitive agreements to acquire EOFlow Co. Ltd. (KOSDAQ: 294090), manufacturer of the EOPatch® device — a...Read more

Pyxis Oncology to Acquire Apexigen

May 24
Last Trade: 3.33 0.02 0.60

Pyxis Oncology positioned at forefront of Antibody-Drug Conjugate (ADC) development Commercially and clinically validated APXiMAB platform for antibody generation complements FACT ADC toolkit of linkers, payloads and conjugation chemistries previously obtained from Pfizer Sotigalimab, a potential best-in-class Phase 2 CD40 agonist, has demonstrated rapid, deep and durable responses across difficult-to-treat tumor types All-stock deal...Read more

CohBar and Morphogenesis Enter into Definitive Merger Agreement to Advance an Innovative Late-stage Clinical Immuno-oncology Pipeline of Therapies to Overcome Resistance to Cancer Immunotherapy

May 23
Last Trade: 2.86 0.16 5.93

Combined company will operate under the name “TuHURA Biosciences, Inc.” and advance a personalized cancer vaccine platform and preclinical tumor microenvironment modulators Lead asset, IFx-Hu2.0, expected to enter Phase 2/3 registration trial as first-line treatment for Merkel Cell Carcinoma in early 2024 $15 million PIPE financing to close concurrent with the closing of the proposed merger – combined company expected to have cash...Read more

Ironwood Pharmaceuticals Enters into Definitive Agreement to Acquire VectivBio, a Clinical-Stage Biotech Company Pioneering Novel Treatments for Severe Rare Gastrointestinal Diseases

May 22
Last Trade: 11.03 0.15 1.38

Transaction Advances Ironwood’s Vision of Becoming the Leading GI Healthcare Company  Adds apraglutide, Next Generation, Synthetic GLP-2 Analog in Phase 3 for Short Bowel Syndrome with Intestinal Failure (SBS-IF); Potential to become Best-in-Class for SBS-IF  Orphan Drug Designation Received for Treatment of Adult Patients with SBS-IF; Topline Results of Phase 3 Trial Expected by the End of 2023  Ironwood to Commence...Read more

Biodexa Pharmaceuticals Enters into Non-binding Letter of Intent for Proposed Acquisition of Varian Biopharmaceuticals

May 18
Last Trade: 0.09 0.002 2.34

Biodexa Pharmaceuticals Enters into Non-binding Letter of Intent for Proposed Acquisition of Varian Biopharmaceuticals Biodexa Pharmaceuticals PLC (NASDAQ: BDRX) (“Biodexa” or the “Company”), a clinical stage biopharmaceutical company developing a pipeline of products aimed at primary and metastatic cancers of the brain is pleased to announce that it has signed non-binding letter of intent to potentially acquire Varian...Read more

Amgen Responds to FTC Action Re: Proposed Acquisition of Horizon Therapeutics

May 16
Last Trade: 218.07 3.80 1.77

THOUSAND OAKS, Calif., May 16, 2023 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today issued the following statement in response to the U.S. Federal Trade Commission's (FTC) complaint seeking to block the company's proposed acquisition of Horizon Therapeutics plc: "Amgen is disappointed by the FTC's decision and remains committed to completing this acquisition, which will bring significant benefits to patients suffering from very serious rare...Read more

Waters Corporation Completes Acquisition of Light Scattering Leader Wyatt Technology

May 16
Last Trade: 258.77 2.73 1.07

MILFORD, Mass., May 16, 2023 /PRNewswire/ -- Waters™ Corporation (NYSE:WAT) today announced it has completed its acquisition of Wyatt Technology, a pioneer and well-recognized leader in innovative light scattering and field-flow fractionation instruments, software, accessories, and services. With more than 80% of its rapidly growing revenues tied to large molecule applications, Wyatt accelerates Waters' ability to build a...Read more

Syneos Health to be Acquired by a Private Investment Consortium for Approximately $7.1 Billion

Shareholders to Receive $43.00 Per Share in Cash Represents 24% Premium to Unaffected Stock Price MORRISVILLE, N.C., May 10, 2023 (GLOBE NEWSWIRE) -- Syneos Health, Inc. (Nasdaq: SYNH) (“Syneos Health” or the “Company”), a leading fully integrated biopharmaceutical solutions organization, today announced that it has entered into a definitive agreement to be acquired by a consortium of private investment firm affiliates composed of...Read more

Sobi to Acquire CTI BioPharma

May 10
Last Trade: 9.05 0.00 0.00

Transaction Price of $9.10 Per Share Represents Compelling 89% Premium to CTI's Closing Stock Price on May 9, 2023 SEATTLE, May 10, 2023 /PRNewswire/ -- CTI BioPharma (Nasdaq: CTIC) ("CTI"), a commercial biopharmaceutical company focused on the development and commercialization of novel targeted therapies for blood-related cancers, today announced that it has entered into a definitive agreement under which Swedish Orphan Biovitrum...Read more

MultiPlan Acquires Leading Healthcare Data and Analytics Firm Benefits Science LLC

Ushers in a new era of the company, accelerates launch of new Data & Decision Science service line with a world-class data & analytics platform and team at BST NEW YORK / May 09, 2023 / Business Wire / MultiPlan Corporation (NYSE: MPLN) (“MultiPlan” or the “Company”), a leading provider of technology and data-enabled cost management, payment, and revenue integrity solutions to the U.S. healthcare industry, today announced that...Read more

Option Care Health and Amedisys to Combine Creating a Leading, Independent Platform for Home and Alternate Site Care

All-Stock Transaction Combines Highly Complementary Businesses Unlocking Significant Benefits for Patients, Providers, Payers, and Care Teams Increases Access to High Quality Care for Communities Across the U.S. through a Unique National Clinical Platform Comprehensive Capabilities Across Alternate Site Care Spectrum Position Combined Company to Move Deeper into Value-Based Care Highly Attractive Combined Financial Profile Which...Read more

Magenta Therapeutics and Dianthus Therapeutics Announce Merger Agreement

May 3
Last Trade: 0.72 0.04 5.15

Merger to create Nasdaq-listed, clinical-stage biotechnology company focused on advancing Dianthus’ portfolio of next-generation antibody complement therapeutics Combined company is expected to have approximately $180 million of cash or cash equivalents at close, including approximately $70 million from a concurrent private financing by Dianthus’ new and existing investors, which is expected to provide funding into mid-2026 Cash...Read more

Stryker completes acquisition of Cerus Endovascular

May 2
Last Trade: 278.30 -0.27 -0.10

KALAMAZOO, Michigan, USA, May 2, 2023 /PRNewswire/ -- Stryker (NYSE:SYK), one of the world's leading medical technology companies, announced today that it has completed the acquisition of Cerus Endovascular Ltd., a privately held, commercial-stage, medical device company engaged in the design and development of neurointerventional devices for the treatment of intracranial aneurysms. Cerus Endovascular's CE Marked products, the Contour...Read more

CVS Health completes acquisition of Oak Street Health

May 2
Last Trade: 69.99 1.11 1.61

WOONSOCKET, R.I., May 2, 2023 /PRNewswire/ -- CVS Health® (NYSE: CVS) today announced it has completed its acquisition of Oak Street Health. The acquisition will broaden CVS Health's value-based primary care platform and significantly benefit patients' long-term health by improving outcomes and reducing costs – particularly for those in underserved communities. On February 8, 2023, CVS Health announced it entered into a definitive...Read more

Aptorum Therapeutics Enters Into Letter of Intent and Term Sheet with Universal Sequencing Technology Corporation to Merge with Aptorum Group’s Subsidiary Paths Innovations Limited

May 1
Last Trade: 3.01 -0.07 -2.27

NEW YORK & LONDON & PARIS / May 01, 2023 / Business Wire / Aptorum Group Limited (Nasdaq: APM, Euronext Paris: APM) (“Aptorum Group” or “Company”), today announced that its wholly owned subsidiary Aptorum Therapeutics Limited (“ATL”) has entered into a non-binding Letter of Intent and Term Sheet (“Term Sheet”) to merge (“Transaction”) its 100% subsidiary, Paths Innovation Limited and its underlying business (collectively...Read more

Astellas Enters into Definitive Agreement to Acquire Iveric Bio

April 30
Last Trade: 38.03 0.24 0.64

Companies to Create World-Class Ophthalmology Entity Lead Program, Avacincaptad Pegol for the Potential Treatment of Geographic Atrophy with PDUFA Goal Date of August 19, 2023 Acquisition advances Astellas' Primary Focus on "Blindness & Regeneration" Acquisition price of US$40 per share in cash, representing a total equity value of approximately US$5.9 billion TOKYO and PARSIPPANY, N.J., April 30, 2023 /PRNewswire/ -- Astellas...Read more

Abbott Laboratories Completes Acquisition of Cardiovascular Systems

April 27
Last Trade: 104.20 1.38 1.34

ABBOTT PARK, Ill., April 27, 2023 /PRNewswire/ -- Abbott (NYSE: ABT) today announced it has completed the acquisition of Cardiovascular Systems, Inc. (CSI), a medical device company with an innovative atherectomy system used in treating peripheral and coronary artery disease. The transaction provides Abbott with a complementary solution for treating vascular disease. CSI's leading atherectomy system prepares vessels for angioplasty or...Read more

NuVasive Shareholders Approve Merger Agreement with Globus Medical

April 27
Last Trade: 39.42 0.87 2.26

SAN DIEGO, April 27, 2023 /PRNewswire/ -- NuVasive, Inc. (NASDAQ: NUVA), the leader in spine technology innovation, focused on transforming spine surgery with minimally disruptive, procedurally integrated solutions, today announced that at the special meeting of shareholders held earlier today, its shareholders voted to approve the adoption of the Company's merger agreement with Globus Medical (NYSE: GMED). As previously announced, under...Read more

Biosynex Completes Acquisition of Chembio Diagnostics

Chembio Diagnostics, Inc. becomes the first North American structure controlled by Biosynex in North America STRASBOURG, France, April 27, 2023 (GLOBE NEWSWIRE) -- Biosynex SA (“Biosynex”) (EPA: ALBIO), a French market leader specializing in the design and distribution of rapid tests, today announced it has completed its acquisition of Chembio Diagnostics, Inc. (“Chembio”), a leading point-of-care diagnostics company focused on...Read more

Hoth Therapeutics and Algorithm Sciences Execute Letter of Intent to Merge

April 26
Last Trade: 1.86 -0.04 -2.30

Anthony Zook, formerly of Astra Zeneca, to be named Chairman of The Board Mike Tilton to be named Chief Executive Officer of the Combined Company Algorithm pipeline focused on Pulmonary Arterial Hypertension (PAH) a rare disease with a prevalence of ~100,000 patients in the US NEW YORK, April 26, 2023 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient focused biopharmaceutical company, today...Read more

Assertio to Acquire Spectrum Pharmaceuticals in All Stock and CVR Transaction

April 25
Last Trade: 6.35 -0.08 -1.24

Complementary Commercial Growth Platforms Anticipated to Accelerate ROLVEDON™ (eflapegrastim-xnst) Injection Profitability and Diversify Revenue Streams Combination of Assertio’s Omni-Channel Digital Sales Capabilities and ROLVEDON In-Person Commercial Team to Enhance Market Access and Growth across All Products Transaction Expected to Be Accretive to Assertio’s Adjusted EPS and Operating Cash Flow in 2024 Spectrum Stockholders Will...Read more

Vallon Pharmaceuticals Completes Merger with GRI Bio

April 21
Last Trade: 0.39 0.00 0.00

Combined company will operate as GRI Bio, Inc. and advance innovative pipeline of Natural Killer T (“NKT”) modulating therapies for the treatment of inflammatory, fibrotic and autoimmune diseasesInvestment proceeds expected to fund planned operations of the combined company into mid-2024 Trading on Nasdaq under the ticker symbol “GRI” expected to commence April 24, 2023 PHILADELPHIA, PA, April 21, 2023 (GLOBE NEWSWIRE) -- GRI Bio,...Read more

Aditxt Signs Asset Purchase Agreement to Acquire Fifty Percent Ownership of Global Response Aid – with Rights to Manufacture and Market Broad-Spectrum Antiviral Drug Avigan

April 20
Last Trade: 0.59 0.008 1.37

This agreement is a significant step for Aditxt as it expands its portfolio to include innovative therapies for infectious diseases; Aditxt will partner with global logistics leader Agility to address a growing global market need for effective antivirals RICHMOND, Va. / Apr 20, 2023 / Business Wire / Aditxt,® Inc. (NASDAQ: ADTX) (“Aditxt” or the “Company”), a global innovation company focused on therapeutics and technologies that...Read more

GSK reaches agreement to acquire late-stage biopharmaceutical company BELLUS Health

April 18
Last Trade: 14.63 0.02 0.14

Acquisition further strengthens specialty medicines and respiratory pipeline with camlipixant, a highly selective P2X3 antagonist and potential best-in-class treatment for refractory chronic cough Currently in phase III clinical development with anticipated regulatory approval and launch in 2026 Accretive to adjusted EPS from 2027 with significant sales potential through 2031 LONDON / Apr 18, 2023 / Business Wire / GSK plc (LSE/NYSE:...Read more

Viemed Healthcare Accelerates Growth Through Acquisition of Tennessee Based Home Medical Products

April 18
Last Trade: 9.80 -0.06 -0.61

LAFAYETTE, La., April 18, 2023 (GLOBE NEWSWIRE) -- Viemed Healthcare, Inc. (the “Company” or “Viemed”) (NASDAQ:VMD and TSX:VMD.TO), a national leader in respiratory care and technology-enabled home medical equipment services, announced that it has entered into a definitive agreement to acquire Tennessee based Home Medical Products, Inc. (“HMP”), a large regional provider of respiratory focused home medical solutions. “We are incredibly...Read more

Lobe Sciences Announces the Acquisition of Altemia(TM) & Company

April 18
Last Trade: 0.03 0.00 0.00

Move Affirms Lobe's Position as an Orphan/Rare Disease Drug Development Company and expands portfolio to include 4 Orphan Disease Programs The Company expects to Launch Altemia™, a Medical Food, and Generate Commercial Revenue in the Second Half of 2023 Acquisition also Includes an International License Agreement With Double Digit Royalty and Milestone Payments, Commercial Inventory and Intellectual Property. Vancouver, British...Read more

Leading Independent Proxy Advisory Firm Glass Lewis Joins ISS in Recommending NuVasive Shareholders Vote "FOR" the Proposed Merger with Globus Medical

April 17
Last Trade: 39.42 0.87 2.26

SAN DIEGO, April 17, 2023 /PRNewswire/ -- NuVasive, Inc. (NASDAQ: NUVA), the leader in spine technology innovation, focused on transforming spine surgery with minimally disruptive, procedurally integrated solutions, today announced that proxy advisory firm, Glass Lewis & Co., LLC ("Glass Lewis"), recommends that NuVasive shareholders vote "FOR" the shareholder proposal to adopt the merger agreement with Globus Medical (NYSE: GMED) at...Read more

SNBL to Acquire Satsuma Pharmaceuticals

April 16
Last Trade: 1.05 -0.02 -1.87

Transaction delivers immediate value and liquidity to Satsuma stockholders SNBL to acquire all outstanding shares of Satsuma for upfront cash consideration of $0.91 per share Satsuma stockholders to also receive non-tradeable CVR of up to $5.77 per share With the goal of maximizing value for stockholders, Satsuma’s Board has carefully considered strategic options for Satsuma and STS101 and fully supports this transaction with...Read more

Merck Strengthens Immunology Pipeline with Acquisition of Prometheus Biosciences

April 16
Last Trade: 198.83 0.18 0.09

PRA023 is a novel, late-stage candidate for ulcerative colitis and Crohn’s disease and other autoimmune conditions Prometheus Biosciences’ comprehensive data set enables target discovery and precision medicine approach in inflammation and immunology RAHWAY, N.J. and SAN DIEGO, April 16, 2023 (GLOBE NEWSWIRE) -- Merck (NYSE: MRK), known as MSD outside the United States and Canada, and Prometheus Biosciences, Inc. (“Prometheus”)...Read more

Shockwave Medical Completes Acquisition of Neovasc

April 11
Last Trade: 289.15 7.49 2.66

SANTA CLARA, Calif., April 11, 2023 (GLOBE NEWSWIRE) -- Shockwave Medical, Inc. (NASDAQ: SWAV) (“Shockwave”), a pioneer in the development of Intravascular Lithotripsy (“IVL”) to treat severely calcified cardiovascular disease, today announced the completion of its previously announced acquisition of Neovasc Inc. (“Neovasc”). The Neovasc Reducer System (the “Reducer”) is a first-of-its-kind technology to address refractory angina....Read more

Thomvest Asset Management Submits Proposal To Acquire Liminal Biosciences On An All Cash Basis

April 5
Last Trade: 6.77 -0.18 -2.59

TORONTO, April 5, 2023 /CNW/ - Thomvest Asset Management Ltd. ("Thomvest") today announced that it has made a non-binding, all cash proposal (the "Proposal") to acquire the outstanding common shares ("Common Shares") of Liminal BioSciences Inc. (Nasdaq: LMNL) (the "Corporation"), other than the 64% owned by Structured Alpha LP ("SALP"), a limited partnership of which Thomvest is the sole general partner, for US$7.50 per Common Share. The...Read more

Mars to Acquire Heska, Global Provider of Advanced Veterinary Diagnostic and Specialty Solutions

April 3
Last Trade: 119.84 -0.01 -0.01

The combination of highly complementary businesses and teams will broaden access to diagnostics and technology, accelerate R&D and innovation, and better serve more veterinary professionals and pets. MCLEAN, Va. and LOVELAND, Colo., April 3, 2023 /PRNewswire/ -- Mars, Incorporated ("Mars"), and Heska Corporation (NASDAQ: HSKA) ("Heska") today announced that they have entered into a definitive agreement under which Mars will...Read more

EIP Pharma and Diffusion Pharmaceuticals Announce Merger Agreement to Create Leading CNS-focused Company Treating Neurodegenerative Diseases

March 30
Last Trade: 3.78 -0.04 -0.92

Combined company will pursue late-stage clinical development of oral neflamapimod for the treatment of dementia with Lewy bodies EIP Pharma to initiate in 2Q 2023 a Phase 2b clinical study, funded in part by a $21 million grant from the National Institute of Aging Combined company expected to have a cash runway through Phase 2b clinical data and to the end of 2024 Transaction has unanimous support of both EIP Pharma and Diffusion...Read more

CVS Health Completes Acquisition of Signify Health

Combined companies will deliver a superior health care experience and drive improved health outcomes WOONSOCKET, R.I., March 29, 2023 /PRNewswire/ -- CVS Health® (NYSE: CVS) today announced that it has completed its acquisition of Signify Health. Signify Health is a leading technology and services company, focused on provider enablement and bringing clinicians into the home to identify chronic conditions, close gaps in care, and...Read more

Jounce Therapeutics Enters Into Agreement to Be Acquired by Concentra Biosciences for $1.85 in Cash per Share Plus Contingent Value Rights

March 27
Last Trade: 1.89 0.00 0.00

CAMBRIDGE, Mass., March 27, 2023 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ: JNCE) (“Jounce” or the “Company”), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, today announced it has entered into a definitive merger agreement whereby Concentra Biosciences, LLC (“Concentra”) will acquire Jounce for $1.85 in cash per share plus a non-tradeable contingent...Read more

Amryt Pharma Shareholders approve acquisition of Amryt Pharma by Chiesi Farmaceutici

March 22
Last Trade: 14.70 0.00 0.00

Transaction Expected to Close in Q2 2023 Dublin, Ireland, March 22, 2023 Amryt Pharma Plc (“Amryt”) (Nasdaq: AMYT), a global, commercial-stage biopharmaceutical company dedicated to acquiring, developing, and commercializing novel treatments for rare diseases, is pleased to announce that all resolutions presented to shareholders at today’s shareholder meetings held to consider and vote on the proposed acquisition of Amryt by Chiesi...Read more

Berkeley Lights Completes Acquisition of IsoPlexis Forming PhenomeX, the Functional Cell Biology Company

March 21
Last Trade: 0.66 -0.02 -2.63

PhenomeX to begin trading under symbol (NASDAQ: CELL) EMERYVILLE, Calif., March 21, 2023 /PRNewswire/ -- Berkeley Lights, Inc. (Nasdaq: BLI), a life sciences tools company, today announced that it has completed its previously announced acquisition of IsoPlexis Corporation (Nasdaq: ISO), a company empowering labs to leverage the cells and proteome changing the course of human health. The newly combined company has been renamed...Read more

CalciMedica Announces Closing of Merger with Graybug Vision and Concurrent Private Placement

March 20
Last Trade: 4.92 0.00 0.00

CalciMedica common stock to commence trading on Nasdaq Global Market on March 21, 2023 under ticker symbol “CALC” Cash and cash equivalents of approximately $34 million as of merger close expected to support operations into the second half of 2024 Phase 2b results in acute pancreatitis for lead product candidate Auxora™ expected in Q4 2023 CalciMedica to host Research and Development Event on April 27, 2023 LA JOLLA, Calif.,...Read more

IMAC Holdings and Brain Scientific Announce a Strategic Merger to Create Synergistic End-To-End Neurological Solution

March 20
Last Trade: 0.95 0.00 0.00

BRENTWOOD, Tenn. and LAKEWOOD RANCH, Fla., March 20, 2023 (GLOBE NEWSWIRE) -- via InvestorWire -- IMAC Holdings, Inc. (“IMAC”) (Nasdaq: BACK), a regenerative rehabilitation company focused on treating musculoskeletal and neurodegenerative disease, and Brain Scientific, Inc. (“Brain Scientific”) (OTCQB:BRSF), a Florida-based applied science technology company, jointly announced today that they have executed a binding Letter of Intent...Read more

Cosmos Health Enters into Definitive Agreement to Acquire ZipDoctor, a Telehealth Company, from American International Holdings

March 17
Last Trade: 3.46 -0.12 -3.35

CHICAGO, IL / ACCESSWIRE / March 17, 2023 / Cosmos Health Inc. ("Cosmos Health" or "the Company") (Nasdaq:COSM), a global healthcare group with proprietary lines of nutraceuticals and distributor of pharmaceuticals, branded generics, OTC medications and medical devices, announced today that it has entered into a definitive agreement to acquire ZipDoctor Inc. from American International Holdings Corp (AMIH) for an undisclosed sum. The Sale...Read more

Statera Biopharma Signs Letter of Intent for Merger with Worksite Labs

March 15
Last Trade: 0.03 -0.06 -64.22

FORT COLLINS, Colo., March 15, 2023 (GLOBE NEWSWIRE) -- Statera Biopharma, Inc. (OTCPK:STAB) (the "Company" or "Statera Biopharma"), a biopharmaceutical company creating next-generation immune therapies that focus on immune restoration and homeostasis, is pleased to announce it has entered into a non-binding letter of intent (the "LOI") with Worksite Labs, Inc. ("WSL"), setting out the initial proposed terms and conditions pursuant to...Read more

Pfizer Invests $43 Billion to Battle Cancer; Enters into Definitive Agreement to Acquire Seagen

March 13
Last Trade: 38.36 0.34 0.89

NEW YORK & BOTHELL, Wash. / Mar 13, 2023 / Business Wire / Pfizer Inc. (NYSE: PFE) and Seagen Inc. (Nasdaq: SGEN) today announced that they have entered into a definitive merger agreement under which Pfizer will acquire Seagen, a global biotechnology company that discovers, develops and commercializes transformative cancer medicines, for $229 in cash per Seagen share for a total enterprise value of $43 billion. The Boards of Directors...Read more

Agilent Technologies Announces Acquisition of e-MSion, Early-Stage Company Behind ECD Technology that Helps Accelerate Drug Development

March 9
Last Trade: 118.22 1.96 1.69

SANTA CLARA, Calif. / Mar 09, 2023 / Business Wire / Agilent Technologies Inc. (NYSE: A) today announced the acquisition of e-MSion, an early-stage company behind the innovative electron capture dissociation (ECD) technology known as the ExD cell. The ExD cell is a compact device for mass spectrometers that enables biological researchers to develop biotherapeutic products more quickly to treat disease. This is done by more comprehensively...Read more

invoX Pharma Completes Acquisition of F-star Therapeutics

March 8
Last Trade: 7.12 0.00 0.00

LONDON / Mar 08, 2023 / Business Wire / invoX Pharma Limited (“invoX”), a U.K.-based wholly-owned subsidiary of Sino Biopharmaceutical Limited (“Sino Biopharm”) (HKEX 1177 HK) with an advancing pipeline of innovative products, today announces that it has successfully completed the acquisition of F-star Therapeutics, Inc. (“F-star”) (NASDAQ:FSTX), a clinical-stage biopharmaceutical company pioneering bispecific antibodies in immunotherapy,...Read more

Neovasc Shareholders Approve Acquisition by Shockwave Medical

March 6
Last Trade: 30.03 0.00 0.00

VANCOUVER, BC, March 06, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – Neovasc Inc. ("Neovasc" or the "Company") (NASDAQ: NVCN)(TSX: NVCN), a leader in the development of minimally invasive devices for the treatment of refractory angina, is pleased to announce that its Shareholders (as defined below) have approved the previously-announced acquisition of all of the outstanding common shares of the Company (the “Shares”) by Shockwave Medical,...Read more

LevelJump Healthcare Acquisition Update

Toronto, Ontario--(Newsfile Corp. - March 6, 2023) - LevelJump Healthcare Corp. (TSXV: JUMP) (OTCQB: JMPHF) (FSE: 75J) ("LevelJump" or the "Company"), a Canadian leader in B2B telehealth solutions, is pleased to announce that it has completed its preliminary due diligence and agreed to amending agreements with the sellers for the proposed Alberta IHF acquisition as announced on November 21, 2022. The purchase price has been reduced to...Read more

agilon health Announces Acquisition of mphrX, a Leading Healthcare Technology Company

March 1
Last Trade: 20.22 0.95 4.93

AUSTIN, Texas / Mar 01, 2023 / Business Wire / agilon health (NYSE: AGL), the trusted partner empowering physicians to transform health care in our communities, today announced it has acquired mphrX, a leading provider of value-based care technology and interoperability solutions. As a result of the transaction, mphrX will become a wholly owned subsidiary of agilon health. “At agilon, we are always looking for opportunities to better...Read more

Adamis Pharmaceuticals and DMK Pharmaceuticals Announce Agreement and Plan of Merger

February 27
Last Trade: 2.07 -0.02 -0.96

Combined company will have commercial products and a library of development candidates, two of which are clinical stage Will be under the leadership of DMK CEO, Dr. Ebrahim (Eboo) Versi MD, PhD Lead development program will be a clinical stage therapeutic under development for the treatment of opioid use disorder SAN DIEGO and SOMERVILLE, N.J., Feb. 27, 2023 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), a...Read more

Rhythm Pharmaceuticals Announces Acquisition of Xinvento B.V. and Portfolio of Investigational Therapeutics

February 27
Last Trade: 17.85 0.68 3.96

       Rare disease company in preclinical development for congenital hyperinsulinism  Acquisition is strong strategic fit with Rhythm’s rare endocrinology focus and provides meaningful new development opportunity  Expect to initiate clinical development in 2024  BOSTON and AMSTERDAM, Feb. 27, 2023 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage...Read more

Redx Pharma and Jounce Therapeutics Announce Recommended Business Combination

February 23
Last Trade: 1.89 0.00 0.00

Combined group will have a strong clinical pipeline and proven expertise in the discovery and development of highly selective therapeutics for the treatment of cancer and fibrotic disease RXC007, a next-generation selective ROCK2 inhibitor, to lead clinical pipeline; portfolio to include discovery projects from both Redx and Jounce Combined group to be called Redx Inc. listed on Nasdaq under the ticker REDX and led by Redx CEO Lisa...Read more

VBL Therapeutics and Notable Labs Announce Definitive Merger Agreement

February 23
Last Trade: 0.22 -0.01 -5.00

Merger will create Nasdaq-listed, clinical-stage therapeutic platform company developing new precision medicines for patient populations selected through Notable’s proprietary Predictive Precision Medicines Platform (“PPMP”) Notable’s validated PPMP combines multi-dimensional biological assays and machine learning to bio-simulate a patient’s cancer treatment and predict their clinical response to the actual treatment Notable has...Read more

Gilead Sciences Completes Acquisition of Tmunity Therapeutics

February 22
Last Trade: 77.89 1.68 2.20

SANTA MONICA, Calif. / Feb 22, 2023 / Business Wire / Kite, a Gilead Company (NASDAQ: GILD), today announced the completion of the previously announced transaction to acquire Tmunity Therapeutics (Tmunity), a clinical-stage, private biotech company focused on next-generation CAR T-therapies and technologies. The acquisition of Tmunity complements Kite’s existing in-house cell therapy research capabilities by adding additional pipeline...Read more

Elevance Health Announces Closing of BioPlus Acquisition

February 15
Last Trade: 471.02 6.59 1.42

INDIANAPOLIS / Feb 15, 2023 / Business Wire / Elevance Health (NYSE: ELV) today announced the closing of its acquisition of BioPlus, a comprehensive specialty pharmacy subsidiary of CarepathRx, a portfolio company of Nautic Partners. BioPlus provides a complete range of specialty pharmacy services for patients living with complex and chronic conditions, such as cancer, multiple sclerosis, hepatitis C, autoimmune diseases, and rheumatology....Read more

Cytek® Biosciences to Acquire Flow Cytometry and Imaging Business from DiaSorin

February 13
Last Trade: 8.07 -0.12 -1.47

Sale of assets related to Flow Cytometry & Imaging (FCI) Business Unit Acquisition will expand Cytek’s product portfolio to include imaging and menu-based application driven flow cytometry to provide full cell analysis solutions to its customers Transaction is in line with DiaSorin’s strategic priorities communicated to the market after Luminex acquisition Employees associated with commercial, operations, R&D and supporting...Read more

Salona Global Medical Device Provides Acquisitions Update, Highlights from U.S. Roadshow Presentation

February 9
Last Trade: 0.27 0.01 3.85

SAN DIEGO, Feb. 09, 2023 (GLOBE NEWSWIRE) -- Salona Global Medical Device Corporation (“Salona Global,” “SGMD ,” or the ‎‎“Company”) (TSXV:SGMD) today provided an update to its acquisition plans and pipeline. The Company is also publishing an up-to-date presentation for upcoming meetings with U.S. institutional investors. In addition to the pending acquisition of Biodex Medical Systems, Inc. (“Biodex”), previously announced November...Read more

Takeda Pharmaceutical Completes Acquisition of Nimbus Therapeutics’ TYK2 Program Subsidiary

February 8
Last Trade: 16.12 0.23 1.45

OSAKA, Japan & CAMBRIDGE, Mass. / Feb 08, 2023 / Business Wire / Takeda (TSE:4502/NYSE:TAK) today announced that it has completed an acquisition of all shares of Nimbus Lakshmi, Inc. (“Lakshmi”) from Nimbus Therapeutics, LLC (“Nimbus”), on February 8, 2023 (EST), as set forth in the share purchase agreement, following clearance from the United States Federal Trade Commission and a satisfaction of other closing conditions. The agreement...Read more

Opiant Pharmaceuticals Announces CFIUS Approval for Proposed Acquisition by Indivior PLC

February 7
Last Trade: 20.65 0.00 0.00

CFIUS clearance represents the final required regulatory approval to complete the proposed merger Completion remains subject to the approval of Opiant stockholders; a special stockholder meeting to approve the acquisition will be held on March 1, 2023 Indivior and Opiant continue to anticipate completing the proposed merger in the first quarter of 2023 SANTA MONICA, Calif., Feb. 07, 2023 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals...Read more

Lantheus Announces Acquisition of Cerveau Technologies, Expanding Imaging Pipeline into Alzheimer’s Disease

February 6
Last Trade: 88.67 -0.41 -0.46

BEDFORD, Mass., Feb. 06, 2023 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (“Lantheus”) (NASDAQ: LNTH), a company committed to improving patient outcomes through diagnostics, radiotherapeutics and artificial intelligence solutions that enable clinicians to Find, Fight and Follow disease, today announced it has acquired Knoxville-based Cerveau Technologies, Inc. (“Cerveau”). Cerveau’s asset is MK-6240, a second-generation F 18-labeled...Read more

Isoray Completes Merger with Viewpoint Molecular Targeting to Advance New Treatment Paradigm in Targeted Precision Oncology Medicine

February 6
Last Trade: 0.55 0.02 3.20

RICHLAND, Wash. & CORALVILLE, Iowa / Feb 06, 2023 / Business Wire / Isoray, Inc. (NYSE AMERICAN: ISR), a medical technology company and innovator in seed brachytherapy, today announced the successful completion of the merger with privately-held Viewpoint Molecular Targeting, Inc. The combined companies’ focus will be the advancement of cancer treatments using radiation, radiopharmaceuticals, and imaging technologies so that precision,...Read more

Azenta Announces the Acquisition of Ziath

February 3
Last Trade: 44.21 0.68 1.56

Enhances high-throughput workflow offerings with leading 2D barcode reader BURLINGTON, Mass., Feb. 3, 2023 /PRNewswire/ -- Azenta, Inc. (Nasdaq: AZTA) today announced that it has acquired Ziath, Ltd. and its subsidiaries ("Ziath"). Based in Cambridge, UK, Ziath is a leading provider of 2D barcode readers for life sciences applications. Founded in 2005, Ziath's innovative 2D barcode readers are a key component of the laboratory...Read more

ABP Acquisition to Acquire AlerisLife for $1.31 Per Share

February 3
Last Trade: 1.32 0.00 0.00

NEWTON, Mass. / Feb 03, 2023 / Business Wire / AlerisLife Inc. (Nasdaq: ALR) today announced that it has entered into a definitive agreement with ABP Acquisition LLC, or ABP, under which ABP will acquire all of the outstanding shares of ALR common stock for $1.31 per share in cash, which represents an 85% premium to the average trading price of the last 30 trading days of $0.71 per share. The total consideration to be paid to stockholders...Read more

Tonix Pharmaceuticals Announces Acquisition of Preclinical Infectious Disease Portfolio from Healion Bio

February 2
Last Trade: 1.88 0.00 0.00

The Acquired Portfolio of Infectious Disease Assets Includes a Class of Potential Broad Spectrum Oral Antiviral Agents, TNX-3900 with a Host-Directed Mechanism Tonix Plans to Develop the TNX-3900 Series of Molecules as Oral Antivirals Either as Monotherapy or in Combination with Other Antivirals The TNX-3900 Class of Antivirals Has a Novel Mechanism of Action Based on Inhibition of Certain Cathepsin Proteases which are Required for...Read more

Purple Biotech Expands Pipeline of First-in-Class Therapeutics with Acquisition of Immunorizon and Its Portfolio of Tri-Specific Antibodies for the Treatment of Cancer

February 2
Last Trade: 1.67 -0.05 -2.91

Immunorizon’s lead compound targets 5T4 antigen and conditionally activates T cells and natural killer (NK) cells Conditional activation of T cells is designed to provide a wide therapeutic index for the compound REHOVOT, Israel, Feb. 02, 2023 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class, effective and durable therapies that harness the power of the tumor...Read more

Vistagen Announces Closing of Pherin Pharmaceuticals Acquisition

February 2
Last Trade: 0.13 -0.0086 -6.09

Acquisition eliminates all future royalty payment obligations for PH94B and PH10 and expands Vistagen's pipeline SOUTH SAN FRANCISCO, Calif. / Feb 02, 2023 / Business Wire / Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression, and other central nervous system (CNS) disorders, today announced the closing of its acquisition of...Read more

Biosynex and Chembio Diagnostics Announce Definitive Acquisition Agreement

January 31
Last Trade: 0.45 0.00 0.00

Complementary Technologies, Product Portfolios, and Market Opportunities Expected to Represent Significant Growth Drivers Consolidated Manufacturing, Sales, Marketing, Operations to Provide Synergistic Cost Savings STRASBOURG, France and HAUPPAUGE, N.Y., Jan. 31, 2023 (GLOBE NEWSWIRE) -- Biosynex SA (“Biosynex”) (EPA: ALBIO), a French market leader specializing in the design and distribution of rapid tests, and Chembio Diagnostics,...Read more

SD Biosensor and SJL Partners Complete Transaction to Acquire Meridian Bioscience

CINCINNATI and SEOUL, South Korea, Jan. 31, 2023 /PRNewswire/ -- Meridian Bioscience, Inc. (NASDAQ: VIVO), a leading global provider of diagnostic testing solutions and life science raw materials, and SD Biosensor, Inc. ("SDB") (KOSE: A137310) and SJL Partners LLC ("SJL") (collectively, the "Consortium"), announced today that they have completed the transaction to acquire Meridian. Under the terms of the merger, Meridian...Read more

Charles River Laboratories Acquires SAMDI Tech

January 30
Last Trade: 200.68 4.34 2.21

Proprietary Mass Spectrometry Technology Delivering Innovative High-Throughput Screening Capabilities to Accelerate Drug Discovery Timelines  Advances Partnership Initiated in 2018  WILMINGTON, Mass. / Jan 30, 2023 / Business Wire / Charles River Laboratories International, Inc. (NYSE: CRL) announced today that it has acquired SAMDI Tech, Inc, a leading provider of high-quality, label-free high-throughput screening (HTS)...Read more

Elevance Health to Acquire Blue Cross and Blue Shield of Louisiana

January 23
Last Trade: 471.02 6.59 1.42

INDIANAPOLIS / Jan 23, 2023 / Business Wire / Elevance Health, Inc. (NYSE: ELV) and Blue Cross and Blue Shield of Louisiana announced today that the companies have entered into a definitive agreement through which Elevance Health agrees to acquire Blue Cross and Blue Shield of Louisiana (BCBSLA). BCBSLA will join Elevance Health’s affiliated Anthem Blue Cross Blue Shield family of brands. This acquisition will unite two organizations...Read more

AstraZeneca Begins Tender Offer to Acquire CinCor Pharma

January 23
Last Trade: 72.59 -0.25 -0.34

WILMINGTON, Del. / Jan 23, 2023 / Business Wire / AstraZeneca is commencing today, through a subsidiary, a tender offer to purchase all outstanding shares of CinCor Pharma, Inc. (CinCor), for $26 per share in cash at closing, plus a non-tradable contingent value right of $10 per share in cash payable upon a specified regulatory submission for a baxdrostat product. On 9 January 2023, AstraZeneca announced that it had entered into a...Read more

VitalHub Announces Acquisition of Coyote Software

January 23
Last Trade: 2.74 0.04 1.48

TORONTO, Jan. 23, 2023 (GLOBE NEWSWIRE) -- VITALHUB CORP. (TSX: VHI) (OTCQX:VHIBF) (the “Company” or “VitalHub”) is pleased to announce today that it has acquired (the “Acquisition”) Coyote Software Corporation (“Coyote”), a company incorporated and existing under the laws of the Province of Ontario. Coyote specializes in tailored software solutions that streamline the workflows of health and social service organizations. The solutions...Read more

Sun Pharma to Acquire Concert Pharmaceuticals, Advancing the Potential Treatment of Alopecia Areata

January 19
Last Trade: 8.37 0.00 0.00

Adds Deuruxolitinib, a Potential Best-in-Class Oral JAK Inhibitor for the Treatment of Alopecia Areata, an Autoimmune Dermatological Disease Leverages Sun Pharma’s Global Infrastructure to Provide Broad Access to Deuruxolitinib for Patients with Alopecia Areata Strengthens Sun Pharma’s Global Dermatology Franchise by Adding a Late-Stage Product in an Area with Significant Unmet Need Sun Pharma to Commence Tender Offer to Acquire All...Read more

Shockwave Medical Announces Agreement to Acquire Neovasc

January 17
Last Trade: 289.15 7.49 2.66

Neovasc’s Innovative Reducer System Will Target the Estimated $5 Billion Refractory Angina Market Shockwave Medical Announces Preliminary Fourth Quarter and Full Year 2022 Revenues and Full Year 2023 Revenue Guidance SANTA CLARA, Calif., Jan. 17, 2023 (GLOBE NEWSWIRE) -- Shockwave Medical, Inc. (NASDAQ: SWAV), a pioneer in the development of Intravascular Lithotripsy (IVL) to treat severely calcified cardiovascular disease, today...Read more

Leap Therapeutics Acquires Flame Biosciences

January 17
Last Trade: 0.88 -0.05 -5.70

Adds FL-301, clinical stage anti-Claudin18.2 antibody, and two preclinical antibody programs to Leap's pipeline Combined cash balance of approximately $115 million enhances runway to mid-2025, fully-funding advancement of DKN-01 and FL-301 Leap to host conference call at 9:00 a.m. ET today CAMBRIDGE, Mass., Jan. 17, 2023 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted...Read more

Elicio Therapeutics and Angion Biomedica Enter into Definitive Merger Agreement

January 17
Last Trade: 18.15 0.00 0.00

Merger to result in Nasdaq-listed company focused on developing immunotherapies based on Elicio’s proprietary lymph node-targeting Amphiphile (AMP) technology Lead program of the combined company will be ELI-002, a therapeutic cancer vaccine targeting mKRAS-driven tumors, currently enrolling a Phase 1 trial for patients with pancreatic ductal adenocarcinoma and colorectal cancer Conference call to be held 8:00 am Eastern Time on...Read more

Core One Labs' Acquires GMP Drug Inc.: Positioning Itself as a Full Cycle Psychedelics Supply Chain Solution for Clinicians, Researchers and Other Drug Developers

January 13
Last Trade: 0.41 0.00 0.00

VANCOUVER, BC / ACCESSWIRE / January 13, 2023 / Core One Labs Inc. (CSE:COOL) (OTCQB:CLABF) (Frankfurt:LD6) (WKN: A3CSSU) (the "Company" or "Core One"), is pleased to announce that it has acquired (the "Acquisition") GMP Drug Inc. ("GMP Drug"), an arms-length privately held company that operates through a Good Manufacturing Practices ("GMP") facility (the "Facility") owned by a third-party located in Ontario, Canada. The Acquisition will...Read more

Merck Completes Tender Offer to Acquire Imago BioSciences

January 11
Last Trade: 112.52 1.59 1.43

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the successful completion of the cash tender offer, through a subsidiary, for all of the outstanding shares of common stock of Imago BioSciences, Inc. (Nasdaq: IMGO), at a purchase price of $36.00 per share in cash, without interest and subject to deduction for any required tax withholding. As of the tender offer expiration at one minute after 11:59...Read more

BioNTech to Acquire InstaDeep to Strengthen Pioneering Position in the Field of AI-powered Drug Discovery, Design and Development

January 10
Last Trade: 108.13 4.01 3.85

Acquisition to enable creation of a fully integrated, enterprise-wide capability to discover, design and develop next-generation immunotherapies at scale by leveraging artificial intelligence and machine learning technologies across BioNTech’s therapeutic platforms and operations Builds on multi-year strategic collaboration between BioNTech and InstaDeep which included the formation of an AI Innovation Lab in 2020 and completion of...Read more

JanOne Completes Acquisition of Soin Therapeutics

January 10
Last Trade: 1.14 -0.06 -5.00

The acquisition of Soin provides JanOne with its second, late stage clinical stage asset LAS VEGAS, Jan. 10, 2023 /PRNewswire/ -- JanOne Inc. ("JanOne") (Nasdaq: JAN), a company that focuses on the development of drugs with non-addictive, pain-relieving properties, announced today that it has completed the acquisition of Soin Therapeutics, LLC and its product, a patent-pending, novel formulation of low-dose naltrexone. This all stock...Read more

Patterson Closes Acquisition of Relief Services for Veterinary Practitioners and Animal Care Technologies

Transaction Expands Patterson Veterinary Capabilities and Offerings Patterson Companies, Inc. (Nasdaq: PDCO), announced that it has, through subsidiaries, successfully completed the previously announced acquisition of substantially all of the assets of Relief Services for Veterinary Practitioners and Animal Care Technologies (“RSVP” and “ACT,” respectively), Texas-based companies that provide innovative solutions to veterinary...Read more

Chiesi Farmaceutici to Acquire Amryt Pharma

January 8
Last Trade: 14.70 0.00 0.00

Transaction expands Chiesi’s rare disease medicine portfolio All cash acquisition at US$14.50 per ADS, plus Contingent Value Rights of up to an additional US$2.50 per ADS based on certain Filsuvez® milestones being achieved Total Transaction value of up to US$1.48 Billion with upfront consideration representing a 107% premium to Amryt ADS’ closing price on January 6, 2023 Transaction unanimously approved and recommended by the...Read more

Assure Announces Acquisition of NervePro

January 6
Last Trade: 0.96 -0.02 -1.74

DENVER, Jan. 06, 2023 (GLOBE NEWSWIRE) -- Assure Holdings Corp. (the “Company” or “Assure”) (NASDAQ: IONM), a provider of intraoperative neuromonitoring (“IONM”) and remote neurology services, is pleased to announce that on December 31, 2022, it completed the acquisition (the “Acquisition”) of substantially all of the assets of Neuroprotect Neuromonitoring, LLC, and certain of its affiliated entities (collectively, “NervePro”), a...Read more

Bruker Announces Acquisition of ACQUIFER Imaging GmbH

January 5
Last Trade: 71.39 0.45 0.63

Adding Big-Data Management and High-Content Screening Solutions for Bioimaging Applications Bruker Corporation (Nasdaq: BRKR) today announced the acquisition of ACQUIFER Imaging GmbH, a pioneer in big-data management solutions for bioimaging and high-content microscopy. This acquisition adds high-performance on-premise processing, secure storage and networking technology that complements Bruker’s advanced fluorescence microscopy...Read more

Sign Up To Get Daily Health Stock News

Please review our Disclaimer and Privacy Policy before subscribing.

Featured Stock

ClearPoint Neuro

ClearPoint Neuro is a global therapy-enabling platform company providing stereotactic navigation and delivery to the brain. Applications of our ClearPoint Neuro Navigation System include electrode lead placement, placement of catheters, and biopsy. The platform has FDA clearance and is...